Change of Adviser

RNS Number : 8483X

Eden Research plc

22 February 2012

 



22 February 2012

GB0001646941/GBP/PLUS-exn

EDEN RESEARCH PLC

("Eden" or the "Company")

Appointment of Zeus Capital as advisor

Eden Research plc, the agrochemical and encapsulation development company, is pleased to announce that as part of its intended AIM admission, Zeus Capital Limited has been appointed as PLUS advisor with immediate effect.

The Directors of Eden are responsible for the contents of this announcement.

Enquiries:

Eden Research plc                                                                                                           01993 862761

Clive Newitt, Managing Director                                                                                             

Zeus Capital Limited                                                                                                      0161 831 1512

Ross Andrews/Brian Stockbridge

Newgate Threadneedle                                                                                                020 7653 9850

Josh Royston, Beth Harris

Notes:

Eden has developed a terpene-based encapsulation technology which uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses.

Terpenes are natural compounds which function as defence mechanisms in many plant groups and are released in response to infection, attack by pests, stress or mechanical injury. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

The next-generation encapsulation technology, licensed from University of Massachusetts Medical School ("UMMS") recently, provides significant additional benefits to the original system as it allows release to be controlled by environmental factors rather than relying solely upon the chemistry of the substances used. This means that there is more control over the timing of the release of the active compound being carried allowing for further reduction in chemicals applied whilst ensuring maximum effectiveness.

The UMMS license also significantly expands the potential use of the Eden technology in non-agricultural applications such as health and beauty, cosmetics and animal health.

For more information about Eden, please visit www.edenresearch.com  

 

END

 

 

APPLLFVRFEILFIF